GlaxoSmithKline Pharmaceuticals announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company also informed about the appointment of a new Head of Ethics & Compliance and the approval of M/s Walker Chandiok & Co LLP as its new statutory auditors for a five-year term. The Board meeting concluded on November 3, 2026.
GlaxoSmithKline Pharmaceuticals Board Meeting Outcome
On November 3, 2026, GlaxoSmithKline Pharmaceuticals Limited convened its Board of Directors meeting where several key decisions were made. The meeting focused on the review and approval of the company’s financial performance and strategic appointments.
Financial Results Approved
The Board approved the Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended September 30, 2026. These results, along with the Limited Review Report from the auditors, were released following the meeting. The financial statements indicate a continuation of the company’s operational activities for the period.
Senior Management and Auditor Appointments
In a move to strengthen its governance framework, the Board appointed Mr. Sandeep Seth as the new Head – Ethics & Compliance, effective from November 3, 2026. Mr. Seth brings over 20 years of experience in ethics, compliance, and governance across various sectors, including pharmaceuticals.
Furthermore, upon the recommendation of the Audit Committee, the Board approved the appointment of M/s Walker Chandiok & Co LLP as the company’s new Statutory Auditors. This appointment is for a first term of five consecutive years, commencing from the financial year 2027-28, subject to shareholder approval at the upcoming Annual General Meeting. M/s Walker Chandiok & Co LLP is a well-established firm of Chartered Accountants with a long history and extensive experience.
Meeting Details
The Board of Directors meeting commenced at 3:45 p.m. and concluded at 6:00 p.m. on November 3, 2026.
Source: BSE
